Company research
KALA BIO, Inc.
CIK 1479419Updated Sep 26, 2026
SecurityKALA · NASDAQ · equity
Name history
KALA BIO, Inc. · through Sep 11, 2026Kala Pharmaceuticals, Inc. · through Jun 23, 2023
KALA price & chart
Loading TradingView…
NASDAQ:KALA on TradingView ↗About the company
KALA is a clinical-stage biopharmaceutical company dedicated to the research, development, and commercialization of innovative therapies for rare and severe diseases of the eye. KALA’s biologics-based investigational therapies utilize KALA’s proprietary mesenchymal stem cell secretome (MSC-S) platform. KALA’s lead product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors. KPI-012 received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing.
In the news
KALA BIO Announces Strategic Initiative to Deploy and Continue to Develop an On-Premises AI Infrastructure Platform for the Biotech Industry; Enters Into Platform Development and Exclusive License Agreement for Proprietary AI Research Platform “Researgency” ↗
Seeking Alpha
Kala Bio rises on plans to leverage AI ↗
Recent filings
DEF 14A filing
PRE 14A filing
Entry into a Material Definitive Agreement
Items 1.01, 9.01
Shareholder Director Nominations · Other Events
Items 5.08, 8.01
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Items 3.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 9,490,000Source | 55,483,000Source | 55,949,000Source | 86,820,000Source |
| Property, Plant and EquipmentUSD | — | 749,000Source | 753,000Source | 400,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 7,557,000Source | 51,181,000Source | 50,895,000Source | 70,495,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | — | — | 195,000Source |
| Assets, CurrentUSD | 9,490,000Source | 52,797,000Source | 52,870,000Source | 85,942,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,933,000Source | 1,616,000Source | 1,975,000Source | 7,657,000Source |
| Operating Lease, Right-of-Use AssetUSD | — | 1,691,000Source | 2,025,000Source | 16,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 2,494,000Source | 43,151,000Source | 48,445,000Source | 67,846,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 1,000Source | — | — | — |
| Common Stock, Value, IssuedUSD | 28,000Source | 6,000Source | 3,000Source | 2,000Source |
| Additional Paid in CapitalUSD | 701,867,000Source | 680,246,000Source | 636,910,000Source | 606,182,000Source |
| Retained Earnings (Accumulated Deficit)USD | -694,900,000Source | -667,920,000Source | -629,409,000Source | -587,210,000Source |
| Stockholders' Equity Attributable to ParentUSD | 6,996,000Source | 12,332,000Source | 7,504,000Source | 18,974,000Source |
| Liabilities and EquityUSD | 9,490,000Source | 55,483,000Source | 55,949,000Source | 86,820,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 2,494,000Source | 16,956,000Source | 8,346,000Source | 25,685,000Source |
| Operating Lease, Liability, CurrentUSD | — | 380,000Source | 334,000Source | 13,000Source |
| Accounts Payable, CurrentUSD | 986,000Source | 628,000Source | 919,000Source | 2,832,000Source |
| Operating Lease, Liability, NoncurrentUSD | — | 1,434,000Source | 1,799,000Source | — |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | — | — | 6,018,000Source | 8,910,000Source |
| Deferred Revenue, CurrentUSD | — | — | — | 4,189,000Source |
| Long-term Debt, Current MaturitiesUSD | — | 10,336,000Source | — | 5,000,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | — | 20,102,000Source | 34,190,000Source | 37,937,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -26,980,000Source | -38,511,000Source | -42,199,000Source | -44,822,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 317,000Source | 259,000Source | 303,000Source | 537,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 6,995,000Source | 8,389,000Source | 7,463,000Source | 7,008,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | -78,000Source | -15,138,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | -7,544,000Source | -1,708,000Source |
| Increase (Decrease) in Accounts PayableUSD | 358,000Source | -291,000Source | -1,904,000Source | -2,076,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -31,991,000Source | -29,382,000Source | -27,927,000Source | -78,908,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -15,000Source | -208,000Source | -429,000Source | 62,717,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -11,618,000Source | 29,876,000Source | 8,506,000Source | -7,942,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -43,624,000Source | 286,000Source | -19,850,000Source | -24,133,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 2,701,000Source | 4,610,000Source | 4,620,000Source | 5,958,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 6,995,000Source | 8,389,000Source | 7,463,000Source | 7,008,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | -667,000Source | 1,248,000Source | 1,253,000Source | 1,425,000Source |
| DepreciationUSD | 216,000Source | 204,000Source | 248,000Source | 421,000Source |
| Gain (Loss) on Disposition of BusinessUSD | — | — | — | 46,995,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | -549,000Source | — | — | — |
| Gain (Loss) on Extinguishment of DebtUSD | 5,793,000Source | — | — | -2,583,000Source |
| General and Administrative ExpenseUSD | 23,629,000Source | 18,340,000Source | — | — |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| InterestExpenseNonoperatingUSD | 3,276,000Source | 5,783,000Source | — | — |
| Investment Income, InterestUSD | 1,140,000Source | 2,056,000Source | 2,711,000Source | 664,000Source |
| Net Income (Loss) Attributable to ParentUSD | -26,980,000Source | -38,511,000Source | -42,199,000Source | -44,822,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -26,980,000Source | -38,511,000Source | -42,199,000Source | -44,822,000Source |
| Nonoperating Income (Expense)USD | 12,181,000Source | 2,472,000Source | -2,536,000Source | 36,884,000Source |
| Operating ExpensesUSD | 39,161,000Source | 40,983,000Source | 39,663,000Source | 85,598,000Source |
| Operating Lease, Impairment LossUSD | 1,411,000Source | — | — | — |
| Other Nonoperating Income (Expense)USD | 5,147,000Source | — | -4,258,000Source | -926,000Source |
| Proceeds from Issuance of Common StockUSD | 9,134,000Source | 3,394,000Source | 18,536,000Source | 1,036,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 0Source | 0Source | 0Source | 3,892,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Selling, General and Administrative ExpenseUSD | — | — | 20,567,000Source | 65,035,000Source |
| Operating Income (Loss)USD | -39,161,000Source | -40,983,000Source | -39,663,000Source | -81,706,000Source |
| Other Nonoperating Income (Expense)USD | 5,147,000Source | — | -4,258,000Source | -926,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -26,980,000Source | -38,511,000Source | -42,199,000Source | -44,822,000Source |
| Earnings Per Share, BasicUSD per share | -3.31Source | -10.15Source | -17.35Source | -29.48Source |
| Earnings Per Share, DilutedUSD per share | -3.31Source | -10.15Source | -17.35Source | -29.48Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 8,148,275Source | 3,796,047Source | 2,432,008Source | 1,520,611Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 8,148,275Source | 3,796,047Source | 2,432,008Source | 1,520,611Source |
| Interest Expense (non-operating)USD | 3,276,000Source | 5,783,000Source | — | — |
| Additional Financial Items | ||||
| General and Administrative ExpenseUSD | 23,629,000Source | 18,340,000Source | — | — |
| Interest ExpenseUSD | — | — | 5,814,000Source | 7,266,000Source |
| Investment Income, InterestUSD | 1,140,000Source | 2,056,000Source | 2,711,000Source | 664,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -26,980,000Source | -38,511,000Source | -42,199,000Source | -44,822,000Source |
| Nonoperating Income (Expense)USD | 12,181,000Source | 2,472,000Source | -2,536,000Source | 36,884,000Source |
| Operating ExpensesUSD | 39,161,000Source | 40,983,000Source | 39,663,000Source | 85,598,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 0Source | 0Source | 0Source | 3,892,000Source |
Filing attachments
kalabio_ex99-1.htm · 8-K · 2026-05-07
EX-99.1 3 kalabio_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 KALA BIO Announces Reverse Stock Split Common Stock Will Begin Trading on Split-Adjusted Basis on May 11, 2026 Arlington, MA, May 7, 2026 (GLOBE NEWSWIRE) - KALA BIO, Inc. (NASDAQ: KALA) (“KALA BIO” or the “Company”), today announced that it intends to effect a reverse stock split of its common stock, par value $0.001 per share (the “common stock”) at a ratio of 1 post-split share for every 50 pre-split shares. The reverse stock split…
Read attachment ↗kalabio_ex99-1.htm · 8-K · 2026-03-04
EX-99.1 3 kalabio_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 KALA BIO Announces Strategic Initiative to Deploy and Continue to Develop an On-Premises AI Infrastructure Platform for the Biotech Industry; Enters Into Platform Development and Exclusive License Agreement for Proprietary AI Research Platform “Researgency” Company launches initiative to become a dedicated AI infrastructure partner for the biotechnology industry — to deploy secure, on-premises AI systems directly within client…
Read attachment ↗kalabio_ex99-1.htm · 8-K · 2026-01-06
EX-99.1 6 kalabio_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 KALA BIO Settles Approximately $10.6 million of Debt ARLINGTON, Mass., January 5, 2026 - KALA BIO, Inc. (NASDAQ:KALA), (“KALA” or the “Company”) today announced the successful completion of its loan settlement with Oxford Finance, LLC (“Oxford”), marking a transformational milestone for the Company. The completion of the settlement resolves critical debt obligations. As previously disclosed in the Company’s Current Report on Form 8-K …
Read attachment ↗kalabio_ex4-1.htm · 8-K · 2025-12-05
EX-4.1 2 kalabio_ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT KALA BIO, INC. Warrant Shares: _______ Initial Exercise Date: December 5, 2025 ──────────────────────────────────────────────────────────────────────── THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinaf…
Read attachment ↗kalabio_ex99-1.htm · 8-K · 2025-12-05
EX-99.1 5 kalabio_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules ARLINGTON, Mass., Dec. 4, 2025 - KALA BIO, Inc. (NASDAQ:KALA) (“KALA” or the “Company”), today announced that it has entered into definitive agreements for the purchase of an aggregate of 10,000,000 shares of its common stock (or pre-funded warrants in lieu thereof), at a purchase price of $1.00 per share (or pre-funded war…
Read attachment ↗kalabio_ex99-2.htm · 8-K · 2025-12-05
EX-99.2 6 kalabio_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 KALA BIO Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules ARLINGTON, Mass., Dec. 5, 2025 - KALA BIO, Inc. (NASDAQ:KALA) (“KALA” or the “Company”), today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase of an aggregate of 10,000,000 shares of its common stock (or pre-funded warrants in …
Read attachment ↗